Literature DB >> 17611206

Trastuzumab--mechanism of action and use in clinical practice.

Clifford A Hudis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17611206     DOI： 10.1056/NEJMra043186

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  809 in total

Review 1.  Quantifying factors for the success of stratified medicine.

Authors:  Mark R Trusheim; Breon Burgess; Sean Xinghua Hu; Theresa Long; Steven D Averbuch; Aiden A Flynn; Alfons Lieftucht; Abhijit Mazumder; Judy Milloy; Peter M Shaw; David Swank; Jian Wang; Ernst R Berndt; Federico Goodsaid; Michael C Palmer
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

Review 2.  Widening the path to personalized medicine.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

3.  Personalized therapeutics: a potential threat to health equity.

Authors:  Michael M Ward
Journal:  J Gen Intern Med       Date:  2012-02-07       Impact factor: 5.128

4.  Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Authors:  E L Carpenter; E A Haglund; E M Mace; D Deng; D Martinez; A C Wood; A K Chow; D A Weiser; L T Belcastro; C Winter; S C Bresler; M Vigny; P Mazot; S Asgharzadeh; R C Seeger; H Zhao; R Guo; J G Christensen; J S Orange; B R Pawel; M A Lemmon; Y P Mossé
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

Review 5.  Molecular prescreening to select patient population in early clinical trials.

Authors:  Jordi Rodón; Cristina Saura; Rodrigo Dienstmann; Ana Vivancos; Santiago Ramón y Cajal; José Baselga; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

6.  Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.

Authors:  Sara A Hurvitz; David J Betting; Howard M Stern; Emmanuel Quinaux; Jeremy Stinson; Somasekar Seshagiri; Ying Zhao; Marc Buyse; John Mackey; Adrian Driga; Sambasivarao Damaraju; Mark X Sliwkowski; Nicholas J Robert; Vicente Valero; John Crown; Carla Falkson; Adam Brufsky; Tadeusz Pienkowski; Wolfgang Eiermann; Miguel Martin; Valerie Bee; Omkar Marathe; Dennis J Slamon; John M Timmerman
Journal:  Clin Cancer Res       Date:  2012-04-13       Impact factor: 12.531

Review 7.  The use of nanoparticulates to treat breast cancer.

Authors:  Xiaomeng Tang; Welley S Loc; Cheng Dong; Gail L Matters; Peter J Butler; Mark Kester; Craig Meyers; Yixing Jiang; James H Adair
Journal:  Nanomedicine (Lond)       Date:  2017-09-04       Impact factor: 5.307

8.  Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.

Authors:  Özge Saatci; Simone Borgoni; Özge Akbulut; Selvi Durmuş; Umar Raza; Erol Eyüpoğlu; Can Alkan; Aytekin Akyol; Özgür Kütük; Stefan Wiemann; Özgür Şahin
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

Review 9.  Recent advances in photodynamic therapy for cancer and infectious diseases.

Authors:  Xutong Shi; Can Yang Zhang; Jin Gao; Zhenjia Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-05-06

10.  A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.

Authors:  Jae-Hyeog Choi; Ki Hyang Kim; Kug-Hwan Roh; Hana Jung; Anbok Lee; Ji-Young Lee; Joo Yeon Song; Seung Jae Park; Ilhwan Kim; Won-Sik Lee; Su-Kil Seo; Il-Whan Choi; Yang-Xin Fu; Sung Su Yea; SaeGwang Park
Journal:  Oncoimmunology       Date:  2018-01-16       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.